Items where authors include "Royle, K-L"

Article

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Gregory, W et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Royle, K-L orcid.org/0000-0003-0225-1199, Coulson, AB, Ramasamy, K et al. (26 more authors) (2022) Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial. BMJ Open, 12 (11). e063037. ISSN 2044-6055

Coulson, AB, Royle, K-L orcid.org/0000-0003-0225-1199, Pawlyn, C et al. (22 more authors) (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 12 (6). e056147. ISSN 2044-6055

Royle, K-L and Cairns, DA orcid.org/0000-0002-2338-0179 (2021) The development and validation of prognostic models for overall survival in the presence of missing data in the training dataset: a strategy with a detailed example. Diagnostic and prognostic research, 5 (1). 14. 14-. ISSN 2397-7523

Cook, G, Royle, K-L, O'Connor, S et al. (20 more authors) (2019) The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. British Journal of Haematology, 185 (3). pp. 450-467. ISSN 0007-1048

Cook, G orcid.org/0000-0003-0223-3652, Royle, K-L, Pawlyn, C et al. (10 more authors) (2019) A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematology, 6 (3). pp. 154-166. ISSN 2352-3026

Royle, K-L, Gregory, WM orcid.org/0000-0003-2641-8416, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (8 more authors) (2018) Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. British Journal of Haematology, 182 (6). pp. 816-829. ISSN 0007-1048

Conference or Workshop Item

Cook, G, Pawlyn, C, Royle, K-L et al. (20 more authors) (2021) Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials. In: 63rd American Society of Hematology Annual Meeting, 11-14 Dec 2021, Atlanta, Georgia, USA.

Royle, K-L, Martin, A orcid.org/0000-0002-2559-6483, Meads, D et al. (2 more authors) (2019) P-103: Considerations for statistical analysis when QALYs are a co-primary endpoint in a large phase II/III randomised controlled trial. In: 5th International Clinical Trials Methodology Conference (ICTMC 2019), 06-09 Oct 2019, Brighton, UK.

Proceedings Paper

Yong, K, Royle, K-L orcid.org/0000-0003-0225-1199, Ramasamy, K et al. (23 more authors) (2022) Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation. In: Blood. 64th ASH Annual Meeting, 10-13 Dec 2022, New Orleans, Louisiana. American Society of Hematology , pp. 1844-1846.

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Ralph, C et al. (17 more authors) (2021) STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC). In: Annals of Oncology. ESMO Congress 2021, 16-21 Sep 2021, Paris, France. Elsevier , S1303-S1304.